YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

Antagonizing vascular endothelial growth factor receptor 2 (VEGFR2) to block angiogenesis has been applied toward cancer therapy for its role in promoting cancer growth and metastasis. However, most these clinical anticancer drugs have unexpected side effects. Development of novel VEGFR2 inhibitors...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Xia, Yong, Song, Xuejiao, Li, Deliang, Ye, Tinghong, Xu, Youzhi, Lin, Hongjun, Meng, Nana, Li, Guobo, Deng, Senyi, Zhang, Shuang, Liu, Li, Zhu, Yongxia, Zeng, Jun, Lei, Qian, Pan, Youli, Wei, Yuquan, Zhao, Yinglan, Yu, Luoting
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4129416/
https://ncbi.nlm.nih.gov/pubmed/25112436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep06031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados